Appia Bio
Lili Yang, Ph.D., is an associate professor of microbiology, immunology, and molecular genetics at UCLA. Her lab is focused on developing gene- and cell-based cancer immunotherapies and she was an integral inventor of Appia’s ACUA technology platform. Previously, Dr. Yang was involved in the scientific founding of Immune Design. She is the recipient of numerous awards: Outstanding New Investigator Award by the American Society of Gene and Cell Therapy; Director’s New Innovator Award from the National Institutes of Health; and, TR35 (Innovators Under 35) Award from the Massachusetts Institute of Technology Review Magazine. Dr. Yang earned her PhD in biology from Caltech studying with Dr. Baltimore.
This person is not in the org chart
This person is not in any offices
Appia Bio
Appia Bio is an early-stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).